Top Page
BioNxt Solutions
(BNXT)
BioNxt Solutions (BNXT) vs. iShares MSCI Canada ETF (EWC)
BioNxt Solutions Business Overview & Revenue Model
BioNxt Solutions Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.82K | 26.98K | 372.25K | 297.44K | 286.50K | 345.65K |
| Gross Profit | -12.51K | 26.98K | 372.25K | 195.62K | 199.48K | 345.65K |
| EBITDA | -4.95M | -4.32M | -6.48M | -11.51M | -19.19M | -16.05M |
| Net Income | -6.18M | -5.31M | -7.72M | -12.38M | -20.64M | -16.89M |
Balance Sheet | ||||||
| Total Assets | 1.23M | 569.36K | 1.27M | 1.61M | 9.73M | 8.28M |
| Cash, Cash Equivalents and Short-Term Investments | 468.76K | 32.35K | 363.65K | 136.20K | 1.35M | 2.58M |
| Total Debt | 8.33M | 4.28M | 4.89M | 4.37M | 5.46M | 3.31M |
| Total Liabilities | 9.54M | 8.43M | 6.55M | 5.74M | 8.06M | 4.28M |
| Stockholders Equity | -8.31M | -7.86M | -5.28M | -4.13M | 1.67M | 4.01M |
Cash Flow | ||||||
| Free Cash Flow | -5.18M | -3.03M | -5.37M | -6.23M | -12.61M | -10.36M |
| Operating Cash Flow | -5.18M | -3.03M | -5.17M | -6.23M | -12.16M | -10.20M |
| Investing Cash Flow | 83.63K | 56.21K | 100.84K | -3.86K | -5.31M | -156.47K |
| Financing Cash Flow | 5.49M | 2.64M | 5.29M | 5.02M | 16.23M | 12.65M |
BioNxt Solutions Technical Analysis
BioNxt Solutions Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | C$90.45M | 129.17 | 0.87% | ― | 2.14% | -83.06% | |
54 Neutral | C$13.15M | -3.83 | -18.39% | ― | 24.30% | -68.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $74.30M | -11.42 | ― | ― | -62.34% | 9.80% | |
46 Neutral | C$4.19M | -0.39 | -664.21% | ― | ― | -80.42% | |
40 Neutral | C$33.74M | -7.50 | -71.80% | ― | -3.94% | -17.62% | |
35 Underperform | C$5.29M | -0.71 | -148.48% | ― | -46.59% | 8.26% |
BioNxt Solutions Corporate Events
BioNxt Solutions Inc. has received a ‘Readiness to Grant’ notification from the Eurasian Patent Organization for its patent application on sublingual delivery of anticancer drugs, specifically for treating autoimmune neurodegenerative diseases. This development is a significant step in BioNxt’s commercialization strategy, as it prepares for a large-mass animal bioequivalence study and further international patent nationalization, enhancing its intellectual property portfolio and market positioning in key global regions.
BioNxt Solutions Inc. has received an ‘Intention to Grant’ notification from the European Patent Office for its sublingual thin-film formulation of cladribine, aimed at treating multiple sclerosis and related diseases. This patent, along with others in Eurasia, strengthens BioNxt’s position in the global market for oral drug delivery, aligning with the trend towards patient-friendly therapies in the European MS market, which is projected to grow significantly. The company’s innovative formulation offers a convenient, non-invasive alternative to traditional treatments, potentially improving patient adherence and quality of life.
BioNxt Solutions Inc. has successfully completed a debt settlement with an arm’s length creditor, resolving $225,010 in debt through the issuance of 112,505 common shares and a cash payment of $112,505. This strategic move helps BioNxt manage its financial obligations while maintaining focus on its core operations and market expansion efforts.
BioNxt Solutions has initiated a large-mass animal bioequivalence study for its lead product, BNT23001, a sublingual Cladribine formulation for multiple sclerosis treatment. This study aims to optimize dosing parameters for an upcoming human bioequivalence study planned for early 2026, potentially enhancing the product’s market positioning by improving drug absorption and patient compliance. The company is also advancing patent nationalization in key global markets, with favorable communications from European and Eurasian patent offices, indicating strong intellectual property protection.
BioNxt Solutions Inc., a bioscience company specializing in innovative drug delivery technologies, has reported significant milestones in its Cladribine sublingual thin-film drug reformulation program for treating multiple sclerosis. The company has completed key technology transfers to its European manufacturing partner, ordered the active pharmaceutical ingredient for a pilot batch, and is preparing for a large-animal bioavailability study. These developments mark crucial steps toward clinical trials and potential market entry, reinforcing BioNxt’s position in the neurological disease treatment market.
BioNxt Solutions Inc. has announced alternative voting methods for its upcoming annual general meeting due to a Canadian postal strike, ensuring shareholders can participate without being physically present. Additionally, the company has engaged Native Ads, Inc. for a comprehensive digital marketing campaign to enhance its market presence, allocating up to $200,000 for this initiative.
BioNxt Solutions Inc. has successfully completed proof-of-concept trials for its Semaglutide oral dissolvable film (ODF) program, marking a significant advancement in their drug delivery technology. The company plans to file a patent and move towards preclinical testing, aiming to offer a non-invasive alternative to existing GLP-1 therapies, which are in high demand globally.
BioNxt Solutions Inc. has announced a significant advancement in its targeted chemotherapy delivery platform, which aims to localize chemotherapy drugs around tumors while minimizing systemic exposure. This novel technology, which employs a dual-action mechanism, has shown in-vitro potential to increase therapeutic effects tenfold while protecting healthy cells. The company is developing a molecule databank to prioritize chemotherapy drugs for further research and has identified a promising candidate currently used in traditional and advanced oncology treatments. BioNxt plans to announce further research steps and patent strategies soon, highlighting its commitment to improving healthcare outcomes.
BioNxt Solutions Inc. has announced the continuation of Terry Lynch as a capital markets advisor, leveraging his extensive experience in the resource and bioscience sectors. Additionally, the company has engaged two investor relations professionals, Rob Grace and Blaine Ruzcki, to enhance investor outreach and communication, which is expected to strengthen BioNxt’s market positioning and stakeholder engagement.
BioNxt Solutions Inc. has successfully completed a debt settlement with an arm’s length creditor, resolving $225,010 in debt through the issuance of 112,505 common shares and a cash payment. This strategic move is part of BioNxt’s ongoing efforts to strengthen its financial position and continue its focus on advancing drug delivery technologies and healthcare solutions in European markets.
BioNxt Solutions Inc. has completed a Track One priority patent filing with the U.S. Patent and Trademark Office for its sublingual thin-film cladribine formulation, aimed at treating multiple sclerosis and other neurological autoimmune diseases. This fast-track patent filing is a strategic move to secure U.S. patent protection, enhancing BioNxt’s intellectual property position and paving the way for bioequivalence studies and commercial partnerships, thereby strengthening its market presence in the drug delivery industry.
BioNxt Solutions Inc. has entered into a debt settlement agreement with a creditor to address $225,010 in outstanding debt. The settlement involves issuing 112,505 common shares and a cash payment of $112,505, subject to regulatory approvals. This move reflects BioNxt’s strategic financial management and could enhance its market positioning by resolving outstanding liabilities.